Adjuvant chemotherapy (CMF) for stage III breast cancer: A randomized trial

D. P. Derman, S. Browde, I. L. Kessel, N. G De Moor, M. Lange, R. Dansey, L. Seymour, W. R. Bezwoda

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

A randomized trial of the effect of adjuvant CMF chemotherapy in patients with Stage III breast cancer receiving primary local radiation or local radiation plus surgery, failed to reveal a survival benefit from early systemic treatment. The subset of premenopausal patients receiving chemotherapy did, however, show a significant prolongation of disease-free survival from 23 to 55 months. Overall survival of this subgroup was not increased. The study included the use of two dose levels of CMF to assess whether higher chemotherapy doses would be more effective. No dose effect was observed. Initial local control with radiation therapy or radiation plus surgery was achieved in the majority (90.9%). Distal recurrence and death from metastatic disease were the major causes of treatment failure. Treatment benefit among premenopausal patients was mainly delayed onset of distal metastatic disease. Among premenopausal patients, salvage therapy for metastatic disease appeared more effective in those not previously exposed to systemic treatment.

Original languageEnglish (US)
Pages (from-to)257-261
Number of pages5
JournalInternational Journal of Radiation Oncology, Biology, Physics
Volume17
Issue number2
DOIs
StatePublished - 1989
Externally publishedYes

Fingerprint

chemotherapy
Adjuvant Chemotherapy
breast
cancer
Breast Neoplasms
Radiation
surgery
dosage
radiation
Drug Therapy
prolongation
Salvage Therapy
Survival
subgroups
Treatment Failure
death
set theory
Disease-Free Survival
radiation therapy
therapy

Keywords

  • Adjuvant chemotherapy
  • Breast cancer
  • Locally advanced

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Derman, D. P., Browde, S., Kessel, I. L., Moor, N. G. D., Lange, M., Dansey, R., ... Bezwoda, W. R. (1989). Adjuvant chemotherapy (CMF) for stage III breast cancer: A randomized trial. International Journal of Radiation Oncology, Biology, Physics, 17(2), 257-261. https://doi.org/10.1016/0360-3016(89)90437-9

Adjuvant chemotherapy (CMF) for stage III breast cancer : A randomized trial. / Derman, D. P.; Browde, S.; Kessel, I. L.; Moor, N. G De; Lange, M.; Dansey, R.; Seymour, L.; Bezwoda, W. R.

In: International Journal of Radiation Oncology, Biology, Physics, Vol. 17, No. 2, 1989, p. 257-261.

Research output: Contribution to journalArticle

Derman, DP, Browde, S, Kessel, IL, Moor, NGD, Lange, M, Dansey, R, Seymour, L & Bezwoda, WR 1989, 'Adjuvant chemotherapy (CMF) for stage III breast cancer: A randomized trial', International Journal of Radiation Oncology, Biology, Physics, vol. 17, no. 2, pp. 257-261. https://doi.org/10.1016/0360-3016(89)90437-9
Derman, D. P. ; Browde, S. ; Kessel, I. L. ; Moor, N. G De ; Lange, M. ; Dansey, R. ; Seymour, L. ; Bezwoda, W. R. / Adjuvant chemotherapy (CMF) for stage III breast cancer : A randomized trial. In: International Journal of Radiation Oncology, Biology, Physics. 1989 ; Vol. 17, No. 2. pp. 257-261.
@article{28a5c510acc044ba9f28e7e3df85fecd,
title = "Adjuvant chemotherapy (CMF) for stage III breast cancer: A randomized trial",
abstract = "A randomized trial of the effect of adjuvant CMF chemotherapy in patients with Stage III breast cancer receiving primary local radiation or local radiation plus surgery, failed to reveal a survival benefit from early systemic treatment. The subset of premenopausal patients receiving chemotherapy did, however, show a significant prolongation of disease-free survival from 23 to 55 months. Overall survival of this subgroup was not increased. The study included the use of two dose levels of CMF to assess whether higher chemotherapy doses would be more effective. No dose effect was observed. Initial local control with radiation therapy or radiation plus surgery was achieved in the majority (90.9{\%}). Distal recurrence and death from metastatic disease were the major causes of treatment failure. Treatment benefit among premenopausal patients was mainly delayed onset of distal metastatic disease. Among premenopausal patients, salvage therapy for metastatic disease appeared more effective in those not previously exposed to systemic treatment.",
keywords = "Adjuvant chemotherapy, Breast cancer, Locally advanced",
author = "Derman, {D. P.} and S. Browde and Kessel, {I. L.} and Moor, {N. G De} and M. Lange and R. Dansey and L. Seymour and Bezwoda, {W. R.}",
year = "1989",
doi = "10.1016/0360-3016(89)90437-9",
language = "English (US)",
volume = "17",
pages = "257--261",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Adjuvant chemotherapy (CMF) for stage III breast cancer

T2 - A randomized trial

AU - Derman, D. P.

AU - Browde, S.

AU - Kessel, I. L.

AU - Moor, N. G De

AU - Lange, M.

AU - Dansey, R.

AU - Seymour, L.

AU - Bezwoda, W. R.

PY - 1989

Y1 - 1989

N2 - A randomized trial of the effect of adjuvant CMF chemotherapy in patients with Stage III breast cancer receiving primary local radiation or local radiation plus surgery, failed to reveal a survival benefit from early systemic treatment. The subset of premenopausal patients receiving chemotherapy did, however, show a significant prolongation of disease-free survival from 23 to 55 months. Overall survival of this subgroup was not increased. The study included the use of two dose levels of CMF to assess whether higher chemotherapy doses would be more effective. No dose effect was observed. Initial local control with radiation therapy or radiation plus surgery was achieved in the majority (90.9%). Distal recurrence and death from metastatic disease were the major causes of treatment failure. Treatment benefit among premenopausal patients was mainly delayed onset of distal metastatic disease. Among premenopausal patients, salvage therapy for metastatic disease appeared more effective in those not previously exposed to systemic treatment.

AB - A randomized trial of the effect of adjuvant CMF chemotherapy in patients with Stage III breast cancer receiving primary local radiation or local radiation plus surgery, failed to reveal a survival benefit from early systemic treatment. The subset of premenopausal patients receiving chemotherapy did, however, show a significant prolongation of disease-free survival from 23 to 55 months. Overall survival of this subgroup was not increased. The study included the use of two dose levels of CMF to assess whether higher chemotherapy doses would be more effective. No dose effect was observed. Initial local control with radiation therapy or radiation plus surgery was achieved in the majority (90.9%). Distal recurrence and death from metastatic disease were the major causes of treatment failure. Treatment benefit among premenopausal patients was mainly delayed onset of distal metastatic disease. Among premenopausal patients, salvage therapy for metastatic disease appeared more effective in those not previously exposed to systemic treatment.

KW - Adjuvant chemotherapy

KW - Breast cancer

KW - Locally advanced

UR - http://www.scopus.com/inward/record.url?scp=0024373629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024373629&partnerID=8YFLogxK

U2 - 10.1016/0360-3016(89)90437-9

DO - 10.1016/0360-3016(89)90437-9

M3 - Article

C2 - 2666363

AN - SCOPUS:0024373629

VL - 17

SP - 257

EP - 261

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 2

ER -